CHOP, in collaboration with Onyx Therapeutics, Inc., is conducting a study for children and young adults up to 21 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT02303821". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.

The purpose of this research study is to determine if certain markers in your blood are increased over the duration of your chemotherapy, especially as you get sicker, such as developing a severe infection (sepsis) or severe respiratory failure (acute respiratory distress syndrome).